Suyun Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Suyun Zhang has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Qiong Luo
Department of Oncology Medicine, Fujian Medical University Union Hospital
4 shared publicationsQixian Zheng
Department of Respiratory and Critical Medicine, Fujian Medical University Union Hospital
3 shared publications- Xiangqi Chen
Department of General Medicine, Fujian Medical University Union Hospital
3 shared publications Haiyu Liu
Department of Respiratory and Critical Medicine, Fujian Medical University Union Hospital
2 shared publicationsNingjing Guo
Fujian Medical University Union Hospital
2 shared publicationsQianyuan Zhang
Department of General Medicine, Fujian Medical University Union Hospital
2 shared publications
Latest Publications
- Open Access
- 15 June 2026
- Published by Frontiers Media SA in Frontiers in Psychology
- Vol. 17, 1820126
Impact of chronic comorbidities on psychological and social status in COVID-19 patients
Objective: To investigate the psychological and social status in patients with COVID-19 accompanied by common chronic diseases compared to patients without these chronic conditions. Additionally, the study aims to explore the relevant influencing factors, providing objective data and scientific theoretical basis for the psychological status of COVID-19 patients with common chronic diseases and improvement of their quality of life. Methods: Sixty patients diagnosed with COVID-19 and admitted to the Department of Respiratory and Critical Care Medicine in Fujian Medical University Union Hospital, between January 1, 2023, and March 31, 2023, were enrolled. The Hospital Anxiety and Depression Scale (HADS), Medical Coping Modes Questionnaire (MCMQ), Social Support Rating Scale (SSRS), and Type D Personality Scale (Ds-14) were used for the investigation. Admission complete blood count, blood biochemistry, and C-reactive protein (CRP) data were collected to calculate the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and C-reactive protein-to-albumin ratio (CAR). The prevalence of anxiety and depression was compared between patients with COVID-19 accompanied by chronic diseases and those without, and coping styles, social support, Type D personality, and CAR were analyzed and compared between the two groups. Results: Among 60 COVID-19 patients, 46 had accompanying chronic diseases, 14 patients had no accompanying chronic diseases. Patients with chronic diseases had higher anxiety and depression scores than those without. Moreover, there were statistically significant differences between the two groups in MCMQ, SSRS, and CAR ( p < 0.05). And we found that, among patients with COVID-19, Type D personality was associated with the co-occurrence of anxiety and depression, as well as with higher anxiety scores. and elevated CAR levels was associated with the co-occurrence of anxiety and depression. Conclusion: The presence of common chronic diseases significantly influenced the coping styles and social support profiles of COVID-19 patients. Different psychosocial factors were associated with the occurrence and severity scores of anxiety and depression in patients.
- 15 June 2026
- Published by Frontiers Media SA in Frontiers in Psychology
- Vol. 17, 1820126
Open AccessImpact of chronic comorbidities on psychological and social status in COVID-19 patients
Objective: To investigate the psychological and social status in patients with COVID-19 accompanied by common chronic diseases compared to patients without these chronic conditions. Additionally, the study aims to explore the relevant influencing factors, providing objective data and scientific theoretical basis for the psychological status of COVID-19 patients with common chronic diseases and improvement of their quality of life. Methods: Sixty patients diagnosed with COVID-19 and admitted to the Department of Respiratory and Critical Care Medicine in Fujian Medical University Union Hospital, between January 1, 2023, and March 31, 2023, were enrolled. The Hospital Anxiety and Depression Scale (HADS), Medical Coping Modes Questionnaire (MCMQ), Social Support Rating Scale (SSRS), and Type D Personality Scale (Ds-14) were used for the investigation. Admission complete blood count, blood biochemistry, and C-reactive protein (CRP) data were collected to calculate the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and C-reactive protein-to-albumin ratio (CAR). The prevalence of anxiety and depression was compared between patients with COVID-19 accompanied by chronic diseases and those without, and coping styles, social support, Type D personality, and CAR were analyzed and compared between the two groups. Results: Among 60 COVID-19 patients, 46 had accompanying chronic diseases, 14 patients had no accompanying chronic diseases. Patients with chronic diseases had higher anxiety and depression scores than those without. Moreover, there were statistically significant differences between the two groups in MCMQ, SSRS, and CAR ( p < 0.05). And we found that, among patients with COVID-19, Type D personality was associated with the co-occurrence of anxiety and depression, as well as with higher anxiety scores. and elevated CAR levels was associated with the co-occurrence of anxiety and depression. Conclusion: The presence of common chronic diseases significantly influenced the coping styles and social support profiles of COVID-19 patients. Different psychosocial factors were associated with the occurrence and severity scores of anxiety and depression in patients.
- Open Access
- 25 October 2025
- Published by Springer Nature in Research Square
A study on the anti-tumor effect and mechanism of arsenic trioxide on lung adenocarcinoma
Background Lung adenocarcinoma is a common malignancy that urgently requires novel pharmacological interventions. Arsenic trioxide (ATO) has demonstrated antitumor activity in various cancers, but its mechanisms of action in lung adenocarcinoma cells remain unclear. Methods The 24-hour half-maximal inhibitory concentration (IC50) of ATO on human lung adenocarcinoma A549 cells was determined using the Cell Counting Kit-8 (CCK-8). Cells treated at this concentration comprised the experimental group, and untreated cells served as the control group. Comparative assessments of cell proliferation, apoptosis, invasion, and migration were performed. Transcriptome sequencing followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses was conducted to identify differentially expressed genes and enriched pathways. Key pathway proteins were validated by Western blot. Results The 24-hour IC50 of ATO was 99.12 µmol/L. Compared with the control group, the ATO-treated group showed inhibited proliferation, increased apoptosis, and reduced invasion and migration (P < 0.05). Transcriptome analysis identified 4,522 upregulated and 4,045 downregulated genes, with enrichment in the mTOR signaling pathway, base excision repair (BER), and apoptosis pathways. At the protein level, total mTOR expression did not change significantly, whereas phosphorylated mTOR (p-mTOR), APE-1, Bcl-2, and Bcl-XL were downregulated, and cleaved caspase-8 and cleaved caspase-9 were upregulated (P < 0.05). Discussion These findings indicate that ATO may suppress the malignant phenotypes of A549 cells by inhibiting mTOR phosphorylation, downregulating key BER components, and activating both extrinsic and intrinsic apoptotic pathways, providing experimental evidence for further investigation of ATO in lung adenocarcinoma therapy.
- 25 October 2025
- Published by Springer Nature in Research Square
Open AccessA study on the anti-tumor effect and mechanism of arsenic trioxide on lung adenocarcinoma
Background Lung adenocarcinoma is a common malignancy that urgently requires novel pharmacological interventions. Arsenic trioxide (ATO) has demonstrated antitumor activity in various cancers, but its mechanisms of action in lung adenocarcinoma cells remain unclear. Methods The 24-hour half-maximal inhibitory concentration (IC50) of ATO on human lung adenocarcinoma A549 cells was determined using the Cell Counting Kit-8 (CCK-8). Cells treated at this concentration comprised the experimental group, and untreated cells served as the control group. Comparative assessments of cell proliferation, apoptosis, invasion, and migration were performed. Transcriptome sequencing followed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses was conducted to identify differentially expressed genes and enriched pathways. Key pathway proteins were validated by Western blot. Results The 24-hour IC50 of ATO was 99.12 µmol/L. Compared with the control group, the ATO-treated group showed inhibited proliferation, increased apoptosis, and reduced invasion and migration (P < 0.05). Transcriptome analysis identified 4,522 upregulated and 4,045 downregulated genes, with enrichment in the mTOR signaling pathway, base excision repair (BER), and apoptosis pathways. At the protein level, total mTOR expression did not change significantly, whereas phosphorylated mTOR (p-mTOR), APE-1, Bcl-2, and Bcl-XL were downregulated, and cleaved caspase-8 and cleaved caspase-9 were upregulated (P < 0.05). Discussion These findings indicate that ATO may suppress the malignant phenotypes of A549 cells by inhibiting mTOR phosphorylation, downregulating key BER components, and activating both extrinsic and intrinsic apoptotic pathways, providing experimental evidence for further investigation of ATO in lung adenocarcinoma therapy.
- Open Access
- 2 April 2024
- Published by Springer Nature in BMC Cancer
- Vol. 24 (1) , 1-12
Knockdown of NCAPD3 inhibits the tumorigenesis of non-small cell lung cancer by regulation of the PI3K/Akt pathway
Background: Accumulating evidence indicates that aberrant non-SMC condensin II complex subunit D3 (NCAPD3) is associated with carcinogenesis of various cancers. Nevertheless, the biological role of NCAPD3 in the pathogenesis of non-small cell lung cancer (NSCLC) remains unclear. Methods: Immunohistochemistry and Western blot were performed to assess NCAPD3 expression in NSCLC tissues and cell lines. The ability of cell proliferation, invasion, and migration was evaluated by CCK-8 assays, EdU assays, Transwell assays, and scratch wound healing assays. Flow cytometry was performed to verify the cell cycle and apoptosis. RNA-sequence and rescue experiment were performed to reveal the underlying mechanisms. Results: The results showed that the expression of NCAPD3 was significantly elevated in NSCLC tissues. High NCAPD3 expression in NSCLC patients was substantially associated with a worse prognosis. Functionally, knockdown of NCAPD3 resulted in cell apoptosis and cell cycle arrest in NSCLC cells as well as a significant inhibition of proliferation, invasion, and migration. Furthermore, RNA-sequencing analysis suggested that NCAPD3 contributes to NSCLC carcinogenesis by regulating PI3K/Akt/FOXO4 pathway. Insulin-like growth factors-1 (IGF-1), an activator of PI3K/Akt signaling pathway, could reverse NCAPD3 silence-mediated proliferation inhibition and apoptosis in NSCLC cells. Conclusion: NCAPD3 suppresses apoptosis and promotes cell proliferation via the PI3K/Akt/FOXO4 signaling pathway, suggesting a potential use for NCAPD3 inhibitors as NSCLC therapeutics.
- 2 April 2024
- Published by Springer Nature in BMC Cancer
- Vol. 24 (1) , 1-12
Open AccessKnockdown of NCAPD3 inhibits the tumorigenesis of non-small cell lung cancer by regulation of the PI3K/Akt pathway
Background: Accumulating evidence indicates that aberrant non-SMC condensin II complex subunit D3 (NCAPD3) is associated with carcinogenesis of various cancers. Nevertheless, the biological role of NCAPD3 in the pathogenesis of non-small cell lung cancer (NSCLC) remains unclear. Methods: Immunohistochemistry and Western blot were performed to assess NCAPD3 expression in NSCLC tissues and cell lines. The ability of cell proliferation, invasion, and migration was evaluated by CCK-8 assays, EdU assays, Transwell assays, and scratch wound healing assays. Flow cytometry was performed to verify the cell cycle and apoptosis. RNA-sequence and rescue experiment were performed to reveal the underlying mechanisms. Results: The results showed that the expression of NCAPD3 was significantly elevated in NSCLC tissues. High NCAPD3 expression in NSCLC patients was substantially associated with a worse prognosis. Functionally, knockdown of NCAPD3 resulted in cell apoptosis and cell cycle arrest in NSCLC cells as well as a significant inhibition of proliferation, invasion, and migration. Furthermore, RNA-sequencing analysis suggested that NCAPD3 contributes to NSCLC carcinogenesis by regulating PI3K/Akt/FOXO4 pathway. Insulin-like growth factors-1 (IGF-1), an activator of PI3K/Akt signaling pathway, could reverse NCAPD3 silence-mediated proliferation inhibition and apoptosis in NSCLC cells. Conclusion: NCAPD3 suppresses apoptosis and promotes cell proliferation via the PI3K/Akt/FOXO4 signaling pathway, suggesting a potential use for NCAPD3 inhibitors as NSCLC therapeutics.
- Open Access
- 25 March 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1358904
Current status and progress of research on the ADP-dependent glucokinase gene
ADP-dependent glucokinase (ADPGK) produces glucose-6-phosphate with adenosine diphosphate (ADP) as the phosphate group donor, in contrast to ATP-dependent hexokinases (HKs). Originally found in archaea, ADPGK is involved in glycolysis. However, its biological function in most eukaryotic organisms is still unclear, and the molecular mechanism of action requires further investigation. This paper provides a concise overview of ADPGK’s origin, biological function and clinical application. It aims to furnish scientific information for the diagnosis and treatment of human metabolic diseases, neurological disorders, and malignant tumours, and to suggest new strategies for the development of targeted drugs.
- 25 March 2024
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 14, 1358904
Open AccessCurrent status and progress of research on the ADP-dependent glucokinase gene
ADP-dependent glucokinase (ADPGK) produces glucose-6-phosphate with adenosine diphosphate (ADP) as the phosphate group donor, in contrast to ATP-dependent hexokinases (HKs). Originally found in archaea, ADPGK is involved in glycolysis. However, its biological function in most eukaryotic organisms is still unclear, and the molecular mechanism of action requires further investigation. This paper provides a concise overview of ADPGK’s origin, biological function and clinical application. It aims to furnish scientific information for the diagnosis and treatment of human metabolic diseases, neurological disorders, and malignant tumours, and to suggest new strategies for the development of targeted drugs.